BOARD OF DIRECTORS
Dr. Robert Melamede, Ph.D. - President and Director
Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. He retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he continues to teach. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabinoids, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede also serves on the Scientific Advisory Board of Americans for Safe Access, the Unconventional Foundation for Autism, The World Aids Institute, Board Tim Brown Foundation (The Berlin Patient), Phoenix Tears Foundation, and regularly consults with professional and lay persons around the world regarding cannabis and health issues. He also served as a director of Newellink Inc, a Colorado-based company specializing in cancer research.
Dr. Dorothy Bray, Ph.D. - Chief Executive Officer and Director
Dr. Dorothy Bray, Ph.D., Former Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline. Dr. Bray held various positions of responsibility at GlaxoSmithKline.
Dr. Bray is the President and owner of ImmunoClin as well as a member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit. As well, Dr. Bray has authored or co-authored multiple publications and has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and developing markets; European Commission Scientific Expert.
Chad S. Johnson - COO, General Counsel and Director
Mr. Johnson, a native of Emporia, Kansas, and resident of Washington, D.C., began his professional career in 1992 after graduating from Harvard College and Harvard Law School. Following a federal judicial clerkship, Mr. Johnson joined the law firm Skadden Arps Slate Meagher & Flom LLP, where he practiced for several years in federal and state financial institution regulatory law with a focus on mergers and acquisitions, serving such clients as Citigroup, Sumitomo Bank, and Travelers. He also performed substantial pro bono work for national LGBT and HIV and AIDS organizations while at Skadden. In 2000, Mr. Johnson left his firm to serve as the Deputy Director of Business Leader Outreach and Deputy Director of Gay and Lesbian Issues for the Gore/Lieberman campaign, after which he served as Executive Director of the National Stonewall Democrats, the only national LGBT gay Democrats organization in the nation. From 2003 to 2012, Mr. Johnson served as chief of staff and general counsel of The Center for Cosmetic Surgery. In addition to other legal, charitable, and business endeavors, in 2010 Mr. Johnson co-founded the World AIDS Institute, a non-profit organization dedicated to document and preserve the global history of AIDS and to strengthen the spectrum of initiatives to find a cure, and more recently in 2012 co-founded with Timothy Ray Brown (the Berlin Patient) and David Purdy, the only charitable organization with a sole mission of finding an HIV cure: the Timothy Ray Brown Foundation. In 2013, Mr. Johnson was appointed to serve as a member of the board of directors, chief operating officer, and general counsel of Endocan Corporation.
Mario Lap - President of European Operations and Director
Mr. Lap brings to the Company a unique combination of expertise in Dutch and greater European medical cannabis law and policy as well as in the areas of health care, IT security, law enforcement, and government relations. Mr. Lap has written numerous international papers and legislative initiatives regarding medical and non-medicinal cannabis laws and access throughout Europe. Mr. Lap has made several television and radio appearances on CNN, BBC, France 2, RTL, and various Dutch public and commercial channels to give public education and information on policy, laws, and current medical breakthroughs.
Mr. Lap, a Dutch health and IT regulatory lawyer in Amsterdam, has extensive experience in Europe with health care and drug policy, medical cannabis regulation, substance use policy, IT project management, digital security policy, food and medicine regulation, and other governmental and private sector consulting. Mr. Lap currently serves as Director, Foundation on Drug Policy and Human Rights, and Director, Drugtext Foundation, and as a Director of various private ventures. Mr. Lap also served as Director of Sales of Apcare B.V., Director of Yalado International B.V., Founder and Director, Calyx Internet B.V. and Calyx Internet Corporation, Professor at the Rechercheschool (Dutch National Police Academy), Head of the Legal and Policy Department of the Netherlands Institute on Alcohol and Other Drugs, and Head of Legal and Policy Department, and Pilot Project of European Monitoring Center on Drugs and Drug Addiction.
Mr. Lap, has an extensive educational background through studies at the Het Amsterdams Lyceum, Colloqium Doctum University of Amsterdam, University of Amsterdam Law School, Open University and University of Liverpool, and speaks fluent Dutch, English, French, and German.
Robert Kane - Chief Financial Officer and Director
Mr. Kane wrote his first business plan in 1996. In 1998, he was hired at Ryan, Beck, and Company, which was bought by the 120-year-old, top ten, financial firm Stifel Nicolaus (NYSE: SF) as a registered representative.
On December 31, 2009, Mr. Kane walked away from the financial markets and started his own firm, Robert Kane Partners, which specializes in business and management planning, investor presentations, and investor relations.
Mr. Kane held the position of Director of Investor Relations for Medical Marijuana, Inc., the first ever publicly traded medical marijuana company. He also held the position of Chief Financial Officer for “Cannabiz Business University.”
Robert Kane's mission is transforming and leading the Medical Cannabis Industry into a viable investment alternative for all types of investors.
Richard Ogden, Ph.D. - Chief Scientific Officer
Dr. Ogden co-founded RORR Inc., a medical, scientific consulting and education company contracted by U.S. and European-based clients, including the International AIDS Society. RORR provides consulting for companies with a focus on viral infectious disease including HIV, Hepatitis C and respiratory viruses.
Beginning his prestigious career as a Post Graduate Chemist at Cambridge University, Dr. Ogden then held several positions at Agouron Pharmaceuticals including Principal Scientist/Manager, New Projects Research, and Director and Senior Director of Scientific Development. Dr. Ogden was also the Senior Director of Scientific Affairs, HIV US Medical at Pfizer Inc.
Dr. Ogden was a team member in the HIV project that led to the discovery and development of Nelfinavir (Viracept).
In working with Pfizer, he had an additional opportunity to work with the Pfizer Foundation in its support of the Academic Alliance and its efforts in Uganda, and with Corporate Philanthropy, in its support of the World Economic Forum and the Global Business Council.
Dr. Ogden received his bachelor's degree in natural sciences and doctorate in synthetic organic chemistry at Cambridge University. His academic career started with postdoctoral research studying RNA transcription and processing at the University of California, San Diego, following which he undertook independent research, funded by the National Science Foundation, in the area of protein and RNA structure-function relationships at the University of California, San Diego and the Agouron Institute.
Mariel Selbovitz, MPH - Vice President of Research Program Development
Ms. Selbovitz is a graduate of the Johns Hopkins School of Public Health and Cornell University and serves as the Chair of the Cornell AIDS Clinical Trials Group Community Advisory Board. Mariel has authored 15 abstracts that have been presented at leading HIV/AIDS conferences around the world. Most recently, she had an oral presentation accepted for publication by Retrovirology on the effect of Probiotics on immunological presentation and preservation of viral-host restrictive factors of Th17 cells in HIV patients. She has also published a number of articles on HIV biomedical interventions and public policy issues, including on the challenges facing the HIV drug pipeline.
Along with basic wet and dry laboratory research coordination at Cannabis Science, Ms. Selbovitz will assist in design of preclinical and early stage protocol development, facilitate collaborative research and development agreements, interaction with NIH Office of Technology Transfer, interface with government sponsored clinical research programs on an international scale, engage in pre-clinical CRO oversight and investigative site management. Ms. Selbovitz will also assist in regulatory affairs, abstract development and other efforts pertinent to the development of CS-TATI-1.
Greta Gaines - Product & Marketing Specialist
Greta Gaines is a leading advocate on the reform of cannabinoid law, spending years becoming an authority while serving on the Board of Directors of the National Organization to Reform Marijuana Law (NORML); the Board of the NORML Women's Alliance Foundation (as a Founding Member); and the Advisory Board of Patients Out of Time. Ms. Gaines is well known as an innovator in the use of hemp and developer of cannabinoid-based solutions as a valuable and healing commodity.